This newsletter is addressed primarily to organisations representing patients, consumers and healthcare professionals. It provides a summary of key information relating to medicines for human use published during the previous month by the European Medicines Agency.

Information is selected based on recommendations from consulted patients, consumers and healthcare professionals, and does not necessarily cover all relevant information published by the Agency.

To receive each new issue of the newsletter, please click here RSS feeds, choose 'Human medicines highlights newsletter' and then click on 'Subscribe to this feed’. Please note, in order to be able to view RSS feeds you need one of the following: a modern web browser; a web-based news reader or a desktop news reader. For a list of RSS readers please refer to our RSS guide and follow the instructions from the selected RSS reader in order to add our newsletter feed.

You can find details on how to cancel / unsubscribe to an RSS feed on the RSS reader tool that you are using, for example Unsubscribe from an RSS Feed for users of Microsoft Outlook.

For further information on the processing of your personal data, please find EMA’s Privacy statement regarding the sending of electronic newsletters click here.

Information on medicines

Antivirals/anti-infectives

New medicines authorised

- **Hepcludex (bulevirtide)**
  Treatment of chronic hepatitis delta virus infection in patients with compensated liver disease

- **Pretomanid FGK (pretomanid)**
  Treatment of tuberculosis

- **Xenleta (lefamulin)**
  Treatment of community-acquired pneumonia

Key to symbols used

〇 Orphan medicine   〇 Generic medicine   〇 biosimilar medicine   〇 Conditional approval   〇 Exceptional circumstances
Cardiovascular system

New medicines authorised

- **Apixaban Accord** (apixaban)
  Treatment and prevention of blood clots and prevention of stroke

Immune system

New medicines authorised

- **Idefirix** (imlifidase)
  Prevention of organ rejection for patients undergoing kidney transplantation

Nephrology (kidney conditions)

New medicines authorised

- **Idefirix** (imlifidase)
  Prevention of organ rejection for patients undergoing kidney transplantation

Respiratory system

New medicines authorised

- **Kaftrio** (elexacaftor / tezacaftor / ivacaftor)
  Treatment of cystic fibrosis

Other medicines

New medicines authorised

- **Gencebok** (caffeine citrate)
  Treatment of primary apnoea (cessation of breathing) in premature newborns
- **Methylthioninium chloride Cosmo** (methylthioninium chloride)
  Diagnostic agent to help visualise lesions in the colon and rectum

Medicines under additional monitoring

- Updated list of medicines under additional monitoring
Other information

Scientific committee and working party activities

- CAT - agendas, minutes and reports
- CHMP - agendas, minutes and highlights
- CHMP - applications for new human medicines: August 2020
- COMP - agendas, minutes and meetings reports
- HMPC - agendas, minutes and meetings reports
- PDCO - agendas, minutes and meeting reports
- PRAC - agendas, minutes and highlights
- PRAC recommendations on safety signals

COVID-19

- COVID-19 What’s new

Other publications

- Communication@EMA – how are we doing?
- Report: Meeting summary - PCWP/HCPWP joint meeting on 2 June 2020
- Report: Meeting summary - PCWP/HCPWP joint meeting on 24 June 2020
- Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products

Events

- EMA Clinical Trial Information System (CTIS) webinar: dynamic demo of sponsor workspace, Virtual meeting, 21 September 2020
Explanation of terms used

**Orphan medicine**
A medicine intended for the treatment of a rare, serious disease. These medicines are granted orphan status during their development; at time of approval, orphan designations are reviewed to determine whether the information available to date allows maintaining the medicine’s orphan status.

**Generic medicine**
A medicine that is essentially the same as one that has already been authorised for use. (The latter is known as the ‘reference medicine’)

**Biosimilar medicine**
A biological medicine that is similar to another biological medicine which has already been authorised for use. (Biosimilar medicines are also known as ‘similar biological’ medicines)

**Conditional approval**
A medicine that fulfils an unmet medical need may, if its immediate availability is in the interest of public health, be granted a conditional marketing authorisation on the basis of less complete clinical data than are normally required, subject to specific obligations being imposed on the authorisation holder to generate complete data on the medicine.

**Exceptional circumstances**
A medicine may be approved in some cases where the applicant cannot provide comprehensive data on the safety or efficacy of the medicine under normal conditions of use, due to exceptional circumstances such as ethical issues or the rarity of the disease concerned. These medicines are subject to specific post-authorisation obligations and monitoring.

**Medicines assessed under Article 58**
Article 58 of Regulation (EC) No 726/2004 allows the CHMP to give opinions, in co-operation with the World Health Organization, on medicinal products that are intended exclusively for markets outside of the European Union.

---

**Note on the centralised authorisation procedure**
To obtain a single marketing authorisation (licence) for a medicine that is valid in all Member States of the European Union (EU) – via a process known as the ‘centralised procedure’ – the company or person developing the medicine must submit an application to the European Medicines Agency.

The Agency’s Committee for Medicinal Products for Human Use (CHMP) carries out a scientific evaluation of the information contained in the application and prepares an opinion (scientific recommendation). The Agency transmits this (positive or negative) opinion to the European Commission, which then issues a Decision granting or refusing the marketing authorisation.

When the CHMP adopts a positive opinion on a medicine, the Agency publishes on its website a ‘summary of opinion’, in the first instance, followed by more detailed information in a ‘European public assessment report (EPAR)’ after the marketing authorisation has been granted.

---

**Visit our website**
Further information about the European Medicines Agency and the work it does is available on our website:
http://www.ema.europa.eu

In particular, you may be interested in these links:
- **About us**
- **Patients and carers**
- **Healthcare professionals**
- **European public assessment reports**

If you have a question relating to the content of this Newsletter, please send it via www.ema.europa.eu/contact

---

**European Medicines Agency**

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

**Address for visits and deliveries** Refer to www.ema.europa.eu/how-to-find-us

**Website** www.ema.europa.eu • **Telephone** +31 (0)88 871 6000

© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged.